News | Ultrasound Imaging | January 07, 2016

New Study Demonstrates Efficacy of Trophon EPR for Ultrasound Probe Disinfection

Results indicate traditional high-level disinfection methods do not completely inactivate human papillomavirus on probes

ultrasound probe disinfection, HPV, Trophon EPR, clinical study, Journal of Medical Virology

January 7, 2016 — A study published by the Journal of Medical Virology demonstrates that the trophon EPR is the only high-level ultrasound disinfection system proven to kill natural, infectious, high-risk, cancer-causing strains of human papillomavirus (HPV).

High-risk HPV accounts for 5 percent of all cancers worldwide, is responsible for almost all cases of cervical cancer and is a leading cause of oral, throat, anal and genital cancers.

A number of published studies have already demonstrated there is a real risk of cross contamination between patients examined with ultrasound probes. The studies showed up to 7 percent of vaginal ultrasound probes remained contaminated with HPV despite the use of probe covers and routine disinfection. HPV is also a very stable virus and is able to remain infectious on fomites and surfaces for days despite routine disinfection.

Testing of natural, infectious “real” HPV has not previously been possible due to the difficulties of growing enough of the natural, infectious virus for research.

This situation changed recently when researchers from Penn State College of Medicine and Brigham Young University in the United States developed a method to grow HPV. “We were the first ever to grow papillomavirus in culture,” said Craig Meyers, distinguished professor of microbiology and immunology, Penn State College of Medicine. “In our original study we chose, specifically, glutaraldehyde and ortho-phthalaldehyde (OPA) to test because these are disinfectants that hospitals believe are sterilants that kill everything, including papillomavirus.”

This original study, which was published in 2014, showed both glutaraldehyde and OPA completely failed to inactivate natural, infectious, high-risk HPV16 – even after 24 hours of contact time. The most recent study used a stringent method in line with U.S. Food and Drug Administration (FDA) requirements for virucidal testing. OPA was retested and the trophon EPR device tested against HPV16 and HPV18, which are the major cancer-causing types of HPV. The results showed that the trophon EPR was the only disinfectant to completely inactivate HPV.

“Our first study showed that commonly used disinfectants are not effective, while this latest study found that trophon EPR was completely effective. The concern is that these other liquid chemical disinfectants are commonly used in medical and healthcare facilities. Where this is happening, HPV is not being killed, posing a risk for transmission,” said Meyers.

The study concluded that healthcare professionals should carefully consider these results when selecting appropriate disinfection methods and that a review of disinfection standards with respect to high-level disinfection may be warranted.

“Publication of the study is very timely given the current increased scrutiny of disinfection practices, said Michael Kavanagh, Nanosonice CEO and president. “An alert issued in the U.S. by the Centers for Disease Control and the FDA in September stipulates that reusable medical devices, such as ultrasound probes, must be properly maintained, cleaned and disinfected/sterilized and urged healthcare facilities to immediately review current reprocessing practices to protect patients.”

According to Kavanagh, the trophon technology uses a proprietary disinfectant containing a high concentration of hydrogen peroxide that is sonically activated to form a sub-micron particle mist. The mist generates a high number of free radicals with superoxidative properties that destroy the virus. Traditionally, ultrasound probes are soaked in toxic liquid chemicals or manually wiped for a few minutes with a pre-impregnated wipe.

For more information: www.nanosonics.com.au

Related Content

Philips Partners With PURE on Tele-Ultrasound Program for Physicians in Rwanda
News | Ultrasound Imaging | October 09, 2019
Philips and non-profit organization PURE (Point-of-care Ultrasound in Resource-limited Environments) highlighted a tele...
Sponsored Content | Whitepapers | Clinical Trials | October 09, 2019
A 2019 N G PX REPORT
AI Accurately Detects Key Chest X-Ray Pneumonia Findings Within 10 Seconds
News | Artificial Intelligence | September 30, 2019
Researchers from Intermountain Healthcare and Stanford University say 10 seconds is about how quickly a new system they...
Samsung to Unveil Hera I10 Ultrasound at SDMS 2019
Technology | Ultrasound Women's Health | September 28, 2019
NeuroLogica, a subsidiary of Samsung Electronics Co. Ltd., announced that the Samsung Hera I10 ultrasound system has...
AI Accurately Predicts Radiotherapy Side Effects for Head and Neck Cancer Patients
News | Artificial Intelligence | September 26, 2019
For the first time, a sophisticated computer model has been shown to accurately predict two of the most challenging...
Machine Learning Could Offer Faster, More Precise Cardiac MRI Scan Results
News | Magnetic Resonance Imaging (MRI) | September 25, 2019
Cardiac magnetic resonance imaging (MRI) analysis can be performed significantly faster with similar precision to...
Partial and Whole-Breast Radiotherapy After Lumpectomy Provide Equally Satisfying Cosmetic Results
News | Radiation Therapy | September 25, 2019
Whole breast radiation and partial breast radiation following a lumpectomy yield similar cosmetic outcomes for women...
Hippocampal Avoidance Using IMRT Now Recommended as Standard of Care for Brain Metastases
News | Radiation Therapy | September 24, 2019
Patients with brain metastases who received whole-brain radiotherapy that avoided memory-specific hippocampal neural...
High-dose Radiation Effective for Men Whose Prostate Cancer Has Spread
News | Prostate Cancer | September 23, 2019
A randomized clinical trial of targeted, high-dose radiation for men with oligometastatic prostate cancer has shown the...